348 related articles for article (PubMed ID: 32297520)
1. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
Cadegiani FA
Am J Physiol Endocrinol Metab; 2020 May; 318(5):E587-E588. PubMed ID: 32297520
[No Abstract] [Full Text] [Related]
2. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
Cadegiani FA; Goren A; Wambier CG
Med Hypotheses; 2020 Oct; 143():110112. PubMed ID: 32721806
[TBL] [Abstract][Full Text] [Related]
3. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
Huang Y; Xie C; Chen X; Hong Q; Huang H
Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834
[No Abstract] [Full Text] [Related]
4. Drugs and the renin-angiotensin system in covid-19.
Aronson JK; Ferner RE
BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880
[No Abstract] [Full Text] [Related]
5. Countermeasure and therapeutic: A(1-7) to treat acute respiratory distress syndrome due to COVID-19 infection.
Soto M; diZerega G; Rodgers KE
J Renin Angiotensin Aldosterone Syst; 2020; 21(4):1470320320972018. PubMed ID: 33169644
[TBL] [Abstract][Full Text] [Related]
6. Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19.
Sparks MA; South A; Welling P; Luther JM; Cohen J; Byrd JB; Burrell LM; Batlle D; Tomlinson L; Bhalla V; Rheault MN; Soler MJ; Swaminathan S; Hiremath S
Clin J Am Soc Nephrol; 2020 May; 15(5):714-716. PubMed ID: 32220930
[No Abstract] [Full Text] [Related]
7. Unexpected BP Sensitivity to Angiotensin II in a Patient With Coronavirus Disease 2019, ARDS, and Septic Shock.
Wang H; Das S; Wieruszewski PM; Taji J; Bartlett B; Azad N; Chowdhury A; Kolar GJ; Jain N; Subla MR; Khan SA
Chest; 2020 Aug; 158(2):e55-e58. PubMed ID: 32335068
[TBL] [Abstract][Full Text] [Related]
8. Central involvement of SARS-CoV-2 may aggravate ARDS and hypertension.
Cure E; Cumhur Cure M; Vatansev H
J Renin Angiotensin Aldosterone Syst; 2020; 21(4):1470320320972015. PubMed ID: 33169637
[No Abstract] [Full Text] [Related]
9. Considerations for Statin Therapy in Patients with COVID-19.
Dashti-Khavidaki S; Khalili H
Pharmacotherapy; 2020 May; 40(5):484-486. PubMed ID: 32267560
[No Abstract] [Full Text] [Related]
10. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?
Patel AB; Verma A
JAMA; 2020 May; 323(18):1769-1770. PubMed ID: 32208485
[No Abstract] [Full Text] [Related]
11. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
Pneumologie; 2020 Sep; 74(9):611-614. PubMed ID: 32916743
[No Abstract] [Full Text] [Related]
12. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?
Esler M; Esler D
J Hypertens; 2020 May; 38(5):781-782. PubMed ID: 32195824
[No Abstract] [Full Text] [Related]
13. [Cardiovascular implications of SARS-CoV-2 infection: A literature review].
García-Saavedra MB; Rosales-Gutiérrez RR; Valverde E; Chumbes-Aguirre M; Alvarado R; Polo R; Azañero R; Chávez C
Medwave; 2020 Aug; 20(7):e8008. PubMed ID: 32877391
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II suppression in SARS-CoV-2 infection: a therapeutic approach.
Lamas-Barreiro JM; Alonso-Suárez M; Fernández-Martín JJ; Saavedra-Alonso JA
Nefrologia (Engl Ed); 2020; 40(3):213-216. PubMed ID: 32456945
[No Abstract] [Full Text] [Related]
15. [Hypertension and RAAS inhibition in times of COVID-19 - current recommendations of the European Society of Hypertension.].
Limbourg FP
MMW Fortschr Med; 2020 May; 162(9):67-69. PubMed ID: 32405833
[TBL] [Abstract][Full Text] [Related]
16. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
Rico-Mesa JS; White A; Anderson AS
Curr Cardiol Rep; 2020 Apr; 22(5):31. PubMed ID: 32291526
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 and Cardiovascular Disease.
Clerkin KJ; Fried JA; Raikhelkar J; Sayer G; Griffin JM; Masoumi A; Jain SS; Burkhoff D; Kumaraiah D; Rabbani L; Schwartz A; Uriel N
Circulation; 2020 May; 141(20):1648-1655. PubMed ID: 32200663
[TBL] [Abstract][Full Text] [Related]
18. Is SARS-CoV-2 associated with liver dysfunction in COVID-19 patients?
Ali N
Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):e84-e86. PubMed ID: 32471656
[No Abstract] [Full Text] [Related]
19. The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients.
Kloc M; Ghobrial RM
Mult Scler Relat Disord; 2020 Oct; 45():102437. PubMed ID: 32763844
[TBL] [Abstract][Full Text] [Related]
20. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
Caocci G; La Nasa G
Ann Hematol; 2020 Jul; 99(7):1675-1676. PubMed ID: 32405693
[No Abstract] [Full Text] [Related]
[Next] [New Search]
